Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

Similar articles for PubMed (Select 8463445)

1.
2.

The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.

Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H.

J Clin Pharmacol. 2001 Dec;41(12):1310-8. Erratum in: J Clin Pharmacol 2002 May;42(5):577-9.

PMID:
11762558
3.

Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients.

Di Salvo TG, O'Gara PT.

Clin Cardiol. 1995 May;18(5):285-90. Review.

PMID:
7628136
4.

Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.

Perrault LP, Denault AY, Carrier M, Cartier R, Bélisle S.

Can J Anaesth. 2000 Mar;47(3):251-4.

PMID:
10730737
5.

Haloperidol-induced torsade de pointes.

O'Brien JM, Rockwood RP, Suh KI.

Ann Pharmacother. 1999 Oct;33(10):1046-50.

PMID:
10534216
6.

[Drug induced QT prolongation].

Altmann D, Eggmann U, Ammann P.

Wien Klin Wochenschr. 2008;120(5-6):128-35. doi: 10.1007/s00508-008-0940-6. Review. German.

PMID:
18365152
7.
8.

A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.

Greco KE, Tune LE, Brown FW, Van Horn WA.

J Clin Psychiatry. 2005 Jul;66(7):928-9.

PMID:
16013910
9.

Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.

Tisdale JE, Kovacs R, Mi D, McCabe GP, Cariera BL, Sharma N, Rosman H.

Pharmacotherapy. 2007 Feb;27(2):175-82.

PMID:
17253907
10.

A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Muzyk AJ, Rivelli SK, Jiang W, Heinz H, Rayfield A, Gagliardi JP.

Drug Saf. 2012 Sep 1;35(9):725-31. doi: 10.2165/11631460-000000000-00000.

PMID:
22876752
11.
12.

Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient.

Akers WS, Flynn JD, Davis GA, Green AE, Winstead PS, Strobel G.

Pharmacotherapy. 2004 Mar;24(3):404-8.

PMID:
15040655
13.

Torsades de Pointes associated with intravenous haloperidol in critically ill patients.

Sharma ND, Rosman HS, Padhi ID, Tisdale JE.

Am J Cardiol. 1998 Jan 15;81(2):238-40.

PMID:
9591913
14.
15.

The association between intravenous haloperidol and prolonged QT interval.

Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y.

J Clin Psychopharmacol. 2001 Jun;21(3):257-61.

PMID:
11386487
16.

Use of haloperidol infusions to control delirium in critically ill adults.

Seneff MG, Mathews RA.

Ann Pharmacother. 1995 Jul-Aug;29(7-8):690-3.

PMID:
8520081
17.

Continuous infusion of haloperidol in agitated, critically ill patients.

Stern TA.

Crit Care Med. 1994 Mar;22(3):378-9. No abstract available.

PMID:
8124985
18.

QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.

Arbel Y, Swartzon M, Justo D.

Anticancer Drugs. 2007 Apr;18(4):493-8.

PMID:
17351403
19.

Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.

Kühlkamp V, Mermi J, Mewis C, Seipel L.

J Cardiovasc Pharmacol. 1997 Mar;29(3):373-81.

PMID:
9125676
20.

Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.

Fongemie JM, Al-Qadheeb NS, Estes NA 3rd, Roberts RJ, Temtanakitpaisan Y, Ruthazer R, Devlin JW.

Pharmacotherapy. 2013 Jun;33(6):589-97. doi: 10.1002/phar.1242. Epub 2013 Mar 25.

PMID:
23529904
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk